PD-L1 functions as an immune checkpoint molecule that suppresses T cell activity by binding to its receptor PD-1, aiding tumor cells in evading immune surveillance.506 Targeted therapies against PD-L1 have become a critical component in the treatment regimens for various cancers.507 Recently, researchers have begun to explore TPD approaches to degrade PD-L1, a novel strategy that shows potential to enhance antitumor immunity by degrading the PD-L1 protein instead of merely blocking signaling pathways. This evidence concerns the gene CD274 and neoplasm.